Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary heart disease

Journal of the American College of Cardiology

Volumn 34, Issue 5, 1999, Pages 1443-1451

  Saku, Keijiro ^a,b   Zhang, Bo ^a   Shirai, Kazuyuki ^a,b   Jimi, Shiro ^a   Yoshinaga, Kazuhiko ^a   Arakawa, Kikuo ^a  

^a Department of Internal Medicine ^*  (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPOLIPOPROTEINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SYNDROME X;

AGED; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERINSULINISM; HYPOLIPOPROTEINEMIAS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; LOGISTIC MODELS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 0033230732     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00372-1     Document Type: Article

References (43)

1. Barter PJ, Rye KA. High density lipoprotems and coronary heart disease. Atherosclerosis 1996;121:1-12.
2. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
4. Rubin EM, Krauss RM, Spanler EA, et al. Inhibition of early atherosclerosis in transgenic mice by human apolipoprotein Al. Nature 1991;353:265-6.
5. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998;19:A31-5.
6. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein A-1 transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899-903.
7. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density hpoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607-11.
8. Plump AS, Erickson SK, Weng W, et al. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest 1996;97:2660-71.
9. Moller LF, Jespersen J. Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk 1995;2:235-40.
10. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
11. Zavaroni I, Bonora E, Paghara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-6.
12. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
13. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809-17.
14. Baillie GM, Sherer JT, Weart CW. Insulin and coronary artery disease: is syndrome X the unifying hypothesis? Ann Pharmacother 1998;32:233-47.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
16. Wynder EL, Stellman SD. Artificial sweetener use and bladder cancer: a case-control study. Science 1980;207:1214-6.
17. Smith AH, Kark JD, Cassel JC, Spears GF. Analysis of prospective epidemiologic studies by minimum distance case-control matching. Am J Epidemiol 1977;105:567-74.
18. Judkins MP. A percutaneous transfemoral technique. Radiology 1967;89:815-21.
19. Saku K, Jimi S, Sasaki N, et al. Reduced coronary vasodilation in patients with familial hypercholesterolemia following intracoronary injection of isosorbide dinitrate. Jpn Circ J 1995;59:808-14.
20. Saku K, Zhang B, Ohta T, et al. Levels of soluble cell adhesion molecules in patients with angiographically defined coronary atherosclerosis. Jpn Circ J 1999;63:19-24.
21. Saku K, Zhang B, Ohta T, Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999;33:436-43.
22. SAS Procedures Guide, Version 6, Third Edition. Cary, NC: SAS Institute Inc., 1990.
23. SAS/STAT User's Guide, Version 6, Fourth Edition, Volume 1. Gary, NC: SAS Institute Inc., 1990.
24. SAS/STAT User's Guide, Version 6, Fourth Edition, Volume 2. Gary, NC: SAS Institute Inc., 1990.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
26. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol 1979;14:109-21.
27. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
28. SAS/STAT Software: changes and enhancements through release 6.11. Cary, NC: SAS Institute Inc., 1996:317-314.
29. Greiner M, Sohr D, Gobel P. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods 1995;185:123-32.
30. Greiner M. Two-graph receiver operating characteristic (TG-ROC): update version supports optimization of cut-off values that minimize overall misclassification costs. J Immunol Methods 1996;191:93-4.
31. Hamashima N. Clinical Studies by Multivanate Analysis: Introduction to Proportional Hazards Model and Logistic Model with Application Programs of SAS. Nagoya, Japan: Nagoya University Publishing House, 1990.
32. Zavaroni I, Dall'Aglio E, Alpi O, et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis 1985;55:259-66.
33. Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967;46:1756-67.
34. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974;57:551-60.
35. Simonson DC, Dzau VJ. Workshop IX - Lipids, insulin, diabetes. Am J Med 1991;90:85s-6s.
36. Stout RW. Insulin and atheroma. 20-yr perspective [see comments]. Diabetes Care 1990;13:631-54.
37. Pfeifle B, Ditschuneit H. Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 1981;20:155-8.
38. Young IR, Stout RW. Effects of insulin and glucose on the cells of the arterial wall: interaction of insulin with dibutyryl cyclic AMP and low density lipoprotein in arterial cells. Diabetes Metab 1987;13:301-6.
39. Oppenheimer MJ, Sundquist K, Bierman EL. Downregulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-I. Diabetes 1989;38:117-22.
40. Krone W, Nagele H, Behnke B, Greten H. Opposite effects of insulin and catecholammes on LDL-receptor activity in human mononuclear leukocytes. Diabetes 1988;37:1386-91.
41. Krone W, Greten H. Evidence for post-transcnptional regulation by insulin of 3-hydroxy-3-methylglutaryl coenzyme A reductase and sterol synthesis in human mononuclear leucocytes. Diabetologia 1984;26:366-9.
42. Shepherd J, Packard CJ. High density lipoprotein metabolism. In: Catapano AL, Bernini F, Corsini A, eds. Atherosclerosis Reviews (Vol. 24). New York: Raven, 1993:17-41.
43. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-mduced expression of endothehal cell adhesion molecules. Arterioscler Thromb Vase Biol 1995;15:1987-94.